Hypercoagulability in COVID-19: from an unknown beginning to future therapies

Ștefania-Teodora Duca\(^1,2\), Alexandru-Dan Costache\(^1,2\), Radu-Ștefan Miftode\(^1,2\), Ovidiu Mitu\(^1,2\), Antoniu-Octavian Petriș\(^1,2\), Irina-Iuliana Costache\(^1,2\)

Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health concern and is characterized by an exaggerated inflammatory response that can lead to a large variety of clinical manifestations such as respiratory distress, sepsis, coagulopathy, and death. While it was initially considered primarily a respiratory illness, different data suggests that COVID-19 can lead to a pro-inflammatory milieu and a hypercoagulable state. Several mechanisms attempt to explain the pro-coagulant state seen in COVID-19 patients, including increased fibrinogen concentration, different receptor binding, exhausted fibrinolysis, cytokine storm, and endothelial dysfunction. Some hematological parameters, such as elevated D-dimers and other fibrinolytic products, indicate that the essence of coagulopathy is massive fibrin formation. Moreover, elevated D-dimer levels have emerged as an independent risk factor for a worse outcome, including death, indicating a potential risk for deep vein thrombosis and pulmonary thromboembolism. Prophylactic anticoagulation is recommended in all in-patients with COVID-19 to reduce the incidence of thrombosis. Those with elevated D-dimer values or with a higher risk of developing thromboembolic events should be treated with higher doses of anticoagulant. Anticoagulation may not be enough in some circumstances, highlighting the need for alternative therapies. An understanding of the complex cross-talk between inflammation and coagulopathy is necessary for developing direct appropriate interventional strategies.

Keywords: COVID-19, coagulopathy, anticoagulant therapy

Introduction
Coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in the last days of 2019 \([1,2]\). The recent coronavirus outbreak had rapidly spread throughout the world, reaching the pandemic denomination by the World Health Organization (WHO) in March 2020 \([3-5]\). The main mode of transmission of COVID-19 is human to human via droplets, the clinical syndrome being characterized by fever, cough and progression to the acute respiratory distress syndrome (ARDS), especially in the elderly and in patients with comorbidities \([2,6-8]\). Patients infected with SARS-CoV-2 are susceptible to a wide range of complications, coagulopathy being one of the most severe complications of the disease \([1,2,6,9,10]\). The risk for various thrombotic events is markedly increased with case series studies reporting a prevalence between 25% to 43%, significantly higher than the incidence in patients without COVID \([1,11,12]\). Several studies suggest that pulmonary embolism (PE) prevalence is 8.3% to 21% of the patients \([13-16]\). It has been suggested that this hypercoagulability may be associated with...
older age, male gender, obesity, Caucasian and African-American ethnicities [1,4,12]. In comparison to venous thrombosis, there have been a few cases of arterial events such as acute coronary syndromes, ischemic strokes and acute limb ischemia [1,4,17,18]. Thus, Lodigiani et al., reported an incidence of acute coronary syndromes of 1.1% in a group of 388 COVID-19 patients [19]. Moreover, microvascular thrombosis are also mentioned in the literature and several clinical reports have shown evidence of thrombotic microangiopathy, especially in lung autopsies [20].

In this review, we discuss the current understanding of potential mechanisms, hematological parameters, management and future therapies of the COVID-19-associated coagulopathy, summarizing the existing literature data until now.

**Brief main headings**

**Pathophysiology of COVID-19 coagulopathy**

Critical illness is known to cause a hypercoagulable state due to mechanical ventilation, immobilization, central venous access devices, and nutritional deficiencies. However, COVID-19 appears to cause a hypercoagulable state through mechanisms unique to SARS-CoV-2 and centers around a complex cross-talk between inflammation and thrombosis [21-23]. COVID-19 causes a severe proinflammatory state, as evident from multiple reports of high C-reactive protein, lactate dehydrogenase, ferritin or interleukin-6 [1,15,24,25]. Researchers presently believe that the central event that triggers the cycle of inflammation and thrombosis originates in the pulmonary alveoli, where SARS-CoV-2 binds to host cells through the angiotensin converting enzyme (ACE) 2 receptor [7,26,27].

SARS-CoV-2 infects host cells via the ACE2 receptor, component of the renin angiotensin aldosterone system (RAAS). RAAS has a central role in regulating blood pressure, mainly through its final effector, Angiotensin II (Ang II), a vasoactive hormone whose effects are mediated by its interaction with specific receptors – Angiotensin II type 1 (AT1) and AT2 (AT3 and AT4 receptors do not have a fully elucidated role). ACE2 is an exopeptidase that catalyzes the conversion of Angiotensin I to the nonapeptide Angiotensins - (1-12) and the conversion of Angiotensin II to Angiotensins 1-7 (Figure 1). ACE2 is expressed especially in vascular endothelial cells, but also in the heart, kidney, nasal and pulmonary cells. Thus, by inactivating Angiotensin II, ACE2 diminishes its adverse effects.

SarsCov2 binds to the ACE2 receptors via a spike protein (S protein) which allows it to enter the host cell. This complex undergoes an endocytosis process that leads to the downregulation of ACE2 phenomena, resulting in the local accumulation of Angiotensin II, which is responsible for severe pulmonary injury (Figure 2).

On the other hand, the blockade of ACE interrupts the chain of events leading to the formation of Angiotensin 1-7 with beneficial effects.

---

**Figure 1.** The renin-angiotensin system cascade, angiotensin receptor 1 inhibitors and angiotensin converting enzyme inhibitors action. Ang I=Angiotensin I; Ang II= Angiotensin II; ACE=Angiotensin converting enzyme; ACE2=Angiotensin converting enzyme 2; AT1R-I= Angiotensin II receptor type 1; AT2R=Angiotensin II receptor type 2; ACE-I=ACE inhibitors; AT1R-I=Angiotensin receptor 1 inhibitors; Mas=Mitochondrial assembly protein.
Upon infection, ACE expression is decreased, leading to Angiotensin II synthesis, that may cause susceptibility to SARS-CoV-2 entry into the tissue [5,7]. Thus, COVID-19 appears to generate worse outcomes in patients with hypertension, cardiovascular disease and diabetes, all of which are associated with reduced baseline levels of ACE2 expression, suggesting an imbalance in ACE1/ACE2 levels [1].

The interleukin (IL)-6 and fibrinogen levels are correlated with each other in COVID-19 patients, supporting the idea of inflammatory thrombosis.

Thus, the trigger event that causes the cycle of inflammation and thrombosis has its origin in the pulmonary alveoli, where SarsCov2 enters through the ACE2 receptor in the alveolar epithelium. Consequently, a severe inflammatory response that outlines the thrombosis scene by multiple mechanisms is initiated [14-22,28-31] (Figure 2).

**Cytokine storm action**

The overproduction of pro-inflammatory cytokines and the overactivation of immune cells during SARS-CoV-2 infection is known as a cytokine storm [5,32]. Higher serum levels of proinflammatory cytokines, such as IL-6, IL-7, IL-1, tumor necrosis factor, interferon- γ have been associated with severe illness and death in multiple studies. The “cytokine storm” contributes to thrombosis through multiple mechanisms, including the activation of neutrophils, monocytes and the endothelium, which generate a prothrombotic state [1,7,33].

**Endothelial activation and dysfunction**

SARS-CoV-2 infection of the endothelial cell and the subsequent endothelial damage leads to endothelial activation and reduced endothelium-dependent vasodilation, resulting in a proinflammatory and procoagulant state [34,35]. The mechanisms of endothelial activation or dysfunction include the inflammatory cytokines, the activation of the complement components in the blood, or are a direct result of the SARS-CoV-2 infection of endothelial cells through the ACE2 receptor [1,20,35].

**Neutrophil extracellular traps**

Neutrophils, which migrate alongside platelets to the site of endothelial damage, contribute significantly to thrombosis. This is due to an important defence mechanism, in which neutrophil release extracellular traps (NETs), a process known as NETosis [1,26]. NETs are described
as extracellular DNA fibers released due to chromatin decondensation and spreading, comprised of histone and cytoplasmic granule proteins. In different conditions, NETs are recognized as linking inflammation, coagulation and thrombosis both on local and systemic levels.

There are several mechanisms which show that NET-driven thrombosis is platelet-dependent [26]. First of all, histone proteins in the DNA fragments of NETs, serve as potent damage-associated molecular patterns which can further attract platelets and thereby initiate a positive feedback loop, inducing platelet aggregation through toll-like receptors on platelets. Secondly, NETs can interact with the von Willebrand factor, released by endothelial cells and platelets, which leads to platelet adhesion and fibrin formation. Additionally, during NETosis, neutrophil elastase, a serine protease, is released, which has previously been shown to inhibit anticoagulation by degrading the tissue factor pathway inhibitor and thrombomodulin. Degradation of these endogenous anticoagulants allows the unprohibited action of the tissue factor, leading to coagulation and thrombosis [26,34].

Complement-mediated microangiopathy

The complement system involves a cascade of processes, culminating in the formation of the terminal C5b-9 membrane attack complex, also observed in COVID-19. Complement activation regulates a proinflammatory response through the actions of C5a which activates both mannann binding lectin serine protease 4 (MASP)-1 and MASP-2. Afterwards, MASP-1 cleaves fibrinogen and factor XIII and therefore activates coagulation and MASP-2 amplifies the complement activity [1,7].

Abnormalities in the fibrinolysis system

Reduced fibrinolysis has been described in severe COVID-19 and increased thromboembolic events occur in patients with severe abnormalities of clot dissolution [34,36]. In severe COVID-19 infections, hypofibrinolysis has been well documented and has been linked to hypercoagulability, increased morbidity and mortality [7,37]. Even though the mechanism of hypofibrinolysis is still poorly understood, a few hypotheses exist. The fibrinolytic inhibitor plasminogen activator inhibitor 1 (PAI-1), which is considered the main responsible factor for the fibrinolysis, is increased in the COVID-19 infection through several mechanisms. Prior studies have shown that Ang II stimulates the expression and release of PAI-1 from the endothelial cells. Ang II perturbs endothelial functions in multiple ways, stimulating the expression of PAI-1 messenger RNA and PAI-1 production in endothelial cells via the AT1 receptor and further increasing plasma PAI-1 levels in a dose-dependent manner. As the binding of SARS-CoV-2 to ACE2 prevents the degradation of Ang II, the excess of Ang II further increases the level of PAI-1 [38,39]. Moreover, inflammation promotes PAI-1 release from endothelial cells, which suppresses urokinase-plasminogen activator and tissue-type plasminogen activator (tPA) from converting plasminogen to plasmin, which ultimately leads to reduced fibrin degradation [34,40]. Finally, PAI-1 expression is enhanced by complement activation, specifically by C5a [7]. All of the mechanisms described above lead to the inhibition of fibrinolysis, causing a hypercoagulable state.

Additional prothrombotic risk factors

Additional mechanisms have been associated with thrombosis in COVID-19. Increased levels of ferritin and elevated antiphospholipid antibody titers in COVID-19 could contribute to inflammation and reflect cellular damage [6,34]. Obesity is a subacute inflammatory condition that is a risk factor for COVID-19 associated coagulopathy [34]. Patients with ARDS resulting in hypoxia have an increased risk of hypoxia-induced endothelial damage [41].

Hematologic laboratory findings in COVID-19

COVID-19 is associated with important findings in both hematology tests and coagulation parameters [1]. The main purpose of these findings is to obtain prognostic information that may be used to assess the level of care, therefore being an indirect indicator of disease severity [12,41]. The International Society on Thrombosis and Hemostasis (ISTH) has proposed the evaluation of different parameters for the prompt recognition of coagulopathy in patients with COVID-19, such as D-dimer levels, prothrombin time, platelet count, and fibrinogen values. Hematologic laboratory findings include thrombocytopenia, lymphopenia, leukopenia and an increased neutrophil to lymphocyte ratio (NLR) [42-45]. Although initial studies from Wuhan reported leukopenia in hospitalized COVID-19 patients, subsequent reports showed that patients who required ICU admission had a higher neutrophil count [1]. Since the lymphocyte count has gained much attention in COVID-19 patients, different studies report the presence of lymphopenia in this setting. An increasing neutrophil count in the setting of lymphopenia (NLR) appears to be a sensitive marker of early inflammation [1,45]. Although thrombocytopenia is considered the most sensitive indicator of sepsis-induced coagulopathy, its incidence is relatively low in COVID-19 and is more pronounced in severe infection [1,19,35]. D-dimers are a marker of fibrin turnover and are an important monitoring test in COVID-19 patients, being also considered an independent predictor of poor outcome, including death [1,15,25].

Management of COVID-19 associated coagulopathy

Treatments that target the hypercoagulable state may reduce the adverse microvascular and macrovascular effects of COVID-19 and these include anticoagulants, antiplatelet therapy, fibrinolytics and immune modulators, but numerous studies are ongoing [34].
Prophylactic versus therapeutic anticoagulant dosage

For COVID-19, prophylactic anticoagulation with low-molecular-weight heparin (LMWH) as early as possible in order to prevent thrombotic events and organ damage is required [11]. The majority of scientific societies recommend antithrombotic prophylaxis with LMWH or unfractionated heparin (UFH) for all admitted patients unless contraindicated [11,12,26,40,41]. For patients who develop venous thromboembolism, these guidelines suggest initial LMWH or UFH followed by the continuation of the same treatment schedule or shifting to warfarin or dabigatran analogues. Thrombolytic therapy is recommended only for acute patients with confirmed PE who show clinical deterioration [21]. In addition, the use of heparin is not only helpful for the anticoagulant effect, but also for its anti-inflammatory properties in patients with COVID-19 [41]. If pharmacological prophylaxis is contraindicated, mechanical prophylaxis (e.g., limb compression) should be considered in immobilized patients [40,46]. It should be noted that dosing recommendations are dynamic, and in the early phases of the pandemic, higher doses of anticoagulation likely helped save the lives of many individuals with severe COVID-19 [12]. It has been recommended to start therapeutic anticoagulation in patients with COVID-19 who have experienced a thromboembolic event or have a strong suspicion of venous thromboembolism [12,41].

Antiplalet therapy

Aspirin would seem to be a logical drug administered in COVID-19 because of its beneficial effects in patients with cardiovascular disease and irreversible antiplatelet effects. It lowers both platelet aggregates in the lung and IL-6 production, which may reduce the cytokine storm [22]. Patients who take low-dose aspirin should continue the therapy. In patients requiring a P2Y12 inhibitor, the drug of choice depends on the COVID-19 specific treatment [41].

Oral anticoagulation therapy

The patients who can have oral medication administrated should be transitioned to an oral anticoagulation therapy, such as a vitamin K antagonist. If there is an option for switching to direct oral anticoagulants (DOACs), it should be taken into consideration, because during isolation for COVID-19, regular international normalized ratio monitoring would likely be difficult [41,47]. Some studies suggested to stop DOAC and shift to heparins due to the DOACs’ interaction with antivirals or immunosuppressive therapy [21].

Fibrinolytic therapy

Fibrin deposition in the alveolar spaces, a known observation in ARDS, is leading to worse respiratory outcomes. Heparin agents are not effective against pre-existing fibrin deposits, although they prevent further fibrin deposition [1]. Thus, other therapeutic options are needed. Few clinical reports have suggested that fibrinolytic therapy may be useful in improving survival in patients with COVID-19. The use of recombinant tissue plasminogen activator (t-PA) to treat ARDS in COVID-19 has been proposed, being associated with temporary improvement in respiratory failure, bleeding complications remaining a major concern of this therapy [11]. A safer approach that may confer benefit in COVID-19 induced ARDS is the use of nebulized plasminogen, leading to improvements in lung function and oxygenation, at least temporary. Therefore, by avoiding the need of using a direct fibrinolytic agent (ie. t-PA), the bleeding risks commonly associated with thrombolysis would be reduced [11,41].

Interactions between antiviral treatment, anticoagulant and antiplatelet therapy

Anticoagulant therapies have several drug-drug interactions, and most include vitamin K antagonists (VKA) and DOACs interactions with antiviral agents (lopinavir/ritonavir) and monoclonal antibodies (tocilizumab and sarilumab) [40]. Thus, antiviral drugs interact with DOACs and may cause significantly increase their blood levels, thus enhancing the risk of bleeding [48]. The effect of DOACs appears to be potentiated by atazanavir, lopinavir/ritonavir, hydroxychloroquine, and decreased by tocilizumab [41]. Atazanavir and lopinavir/ritonavir may also decrease the active metabolite of clopidogrel and prasugrel and increase ticagrelor’s efficacy [1,40]. A list of drug interactions can be found at http://covid19-druginteractions.org [1].

Duration of anticoagulation

The American Society of Hematology recommends that any decision to use extended post-discharge thromboprophylaxis with anticoagulation or aspirin should consider the individual patient’s VTE risk factors, such as reduced mobility, coagulopathy, and bleeding risk. For patients who have been given empirical therapeutic anticoagulation for suspected PE, it is recommended that they should remain anticoagulated for at least 3 months, regardless of the results of future investigation studies. Moreover, cases of confirmed VTE should be considered as “provoked” and treated for a duration of 3-6 months [1].

Future therapeutic targets and areas of research

As previously highlighted, a unique mechanisms of inducing coagulopathy has been observed in COVID-19 [1]. Several other potential therapies targeting endothelial dysfunction or fibrinolysis in COVID-19 patients have been proposed or are currently underway [6]. The experimental use of immunosuppressive agents can potentially halt the bidirectional cross-talk between inflammation and the thrombosis process in COVID-19 patients [1]. Different data showed that treatment with humanized anti-C5a antibody significantly ameliorated lung injury and inflammation. Thereby, complement inhibition with agents such as eculizumab, may also be a promising treatment for severe COVID-19 forms [1]. Different studies propose several mechanisms of either directly targeting the molecules that form NETs, such as IL1β, or the processes that leads to
their formation, since NETs have the potential to initiate and propagate both inflammation and thrombosis [1,49]. As the cytokine storm has an important role in thrombosis, anti-IL drugs may prove their role as a treatment option in affected patients. Studies are required to see the effect of tocilizumab (anti IL-6) and canakinumab (anti IL-1) for the treatment of COVID-19. Anti-Janus kinase and anti-human immunoglobulin G inhibitors may also be potential treatment options [41]. Since the pathogenesis of inflammation and sepsis-induced coagulopathy involves the production of thrombin and the reduction of natural anticoagulant proteins, numerous studies have explored the benefit of using coagulation inhibitors such as antithrombin. In general, these data provide incentive for considering experimental therapies that address physiologic anticoagulant pathways that are most likely inhibited or inactivated in COVID-19 [1,10,40]. There has been development in several research lines evaluating antithrombotic therapies, which are listed on ClinicalTrials.gov.

**Conclusion**

In conclusion, the prothrombotic status in COVID-19 patients is a reality, being responsible for the occurrence of both arterial and venous thrombosis. Increased D-dimer levels are an independent risk factor for the adverse outcomes in patients with COVID-19.

The COVID-19 associated coagulopathy is emerging as a major pathological occurrence with multiple hypercoagulable events, including stroke, myocardial infarction and multisystemic organ failure. Accumulating evidence highlights that the hypercoagulability of SARS-CoV-2 involves a complex interplay of multiple pathways with unique mechanisms of thrombo-inflammation. A better understanding of this pathophysiology will allow to determine the optimal doses of anticoagulation therapies and to study other treatment modalities. Available evidence and guidelines recommend prophylactic anticoagulation with LMWH for all hospitalized patients.

**References**

1. Abou-Ismail MY, Diamond A, Kapoor S, Arafa Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res. 2020;194:101-115.
2. Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung. 2021;50:357-360.
3. Scudiero F, Silverio A, Di Maio A, Russo V, Citro R, Personeni D, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021;198:34-39.
4. Singhania N, Bansal S, Nimmatoori DP, Ejaz AA, McCullough PA, Singhania G. Current Overview on Hypercoagulability in COVID-19. Am J Cardiovasc Drugs. 2020;20:393–403.
5. Sathler PC. Hemostatic abnormalities in COVID-19: A guided review. An Acad Bras Cienc. 2020;92:e20200834.
6. Meizoso JP, Moore HB, Moore EE. Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications. J Am Coll Surg. 2021;232:995-1003.
7. Alam W. Hypercoagulability in COVID-19: A review of the potential mechanisms underlying clotting disorders. SAGE Open Med. 2021;9:20503121211002996.
8. Olson MC, Lubner MG, Menias CO, Mellnick VM, Gettle LM, Kim DH, et al. RadioGraphics Update: Venous Thrombosis and Hypercoagulability in the Abdomen and Pelvis-Findings in COVID-19. Radiographics. 2020;40:E24-E28.
9. Frazer JS, Everden AJT. Emerging patterns of hypercoagulability associated with critical COVID-19: A review. Trends in Anaesthesia & Critical Care 2020;34:4-13.
10. van de Bert TW, Huulhof AM, Nagy M, van Oerle R, Sels JW, van Bussel B, et al. Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability. Thromb Res. 2021;201:84-89.
11. Miesbach W, Makris M. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020;26:1076029620938149.
12. Adam C, Flora P. COVID-19: Hypercoagulability. Up to Date 2021
13. Fletcher-Sandersjöö A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res. 2020;194:36-41.
14. Planquette B, Le Berre A, Khider L, Yannoutsos A, Gendron N, de Torcy M, et al. Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study. Thromb Res. 2021;197:94-99.
15. Canzano P, Brambilla M, Porro B, Cosentino N, Tortorici E, Vicini S, et al. Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients. JACC Basic Transl Sci. 2021;6:202-218.
16. Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18:1738-1742.
17. Aktaa S, Wu J, Nadarajah R, Rashid M, de Belder M, Deanfield J, et al. Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study. Thromb Res. 2021;202:17-23.
18. Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability. Thromb Res. 2020;196:38-51.
19. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan. Italy. Thromb Res. 2020;191:9–14.
Infectious Diseases

20. Kloor FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMP, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

21. Aggarwal M, Dass J, Mahapatra M. Hemostatic Abnormalities in COVID-19: An Update. Indian J Hematol Blood Transfus. 2020;36:1-11.

22. Mazzetti MA, Chow JH, Tanaka K. COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management. Shock. 2021;55:465-471.

23. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability in COVID-19. J Thromb Haemost. 2020;18:1559-1561.

24. Boss K, Kribben A, Tyczynski B. Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients. Thromb J. 2021;19:10.

25. Lorenzo C, Francesca B, Francesco P, Elena C, Luca S, Paolo S. Acute pulmonary embolism in COVID19 related hypercoagulability. J Thromb Thrombolysis. 2020;50:223-226.

26. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67.

27. Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, et al. COVID-19 and Hypercoagulability: A Review. Clin Appl Thromb Hemost. 2020;26:1076029620962853.

28. Bautista-Vargas M, Bonilla-Abadía F, Cañas CA, Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID19. J Thromb Thrombolysis. 2020;50:479-483.

29. Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A, White A, Anderson AS, Chilton R. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Curr Cardiol Rep. 2020;22:53.

30. Arena AW, Hussein A, Kurkowski EJ, Kulkarni ML. Can’t Dissolve Me Now: A COVID-19 Provoked Venous Thromboembolism Breaks Through Apixaban: Case Report. Clin Pract Cases Emerg Med. 2021;5:202-205.

31. Li TS, Lin L. The Pathogenesis of COVID-19 Indicates Therapeutic Strategies. Infectious Diseases & Immunity. 2021;1:5-7.

32. Tan CW, Low JGH, Wong WH, Chua YY, Goh SL, Ng HJ. Critically ill COVID-19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability. Am J Hematol. 2020;95:E156-E158.

33. García-Ortega A, Oscullo G, Calvillo P, López-Reyes R, Méndez R, Gómez-Olivas JD, et al. Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection. J Infect. 2021;82:261-269.

34. Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76:412-420.

35. Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost. 2020;18:2103-2109.

36. Blasi A, von Meijenfeldt FA, Adelmeijer J, Calvo A, Ibañez C, Perdomo J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J Thromb Haemost. 2020;18:2646-2653.

37. Creet-Bulos C, Auld SC, Caridi-Scheible M, Barker NA, Friend S, Gaddh M, et al. Fibrinolysis Shutdown and Thrombosis in a COVID-19 ICU. Shock. 2021;55:316-320.

38. Siddiqi HK, Libby P. COVID-19 – A vascular disease. Trends Cardiovasc Med. 2021;21:1-5.

39. Miesbach W. Pathological Role of Angiotensin II in Severe COVID-19. TH Open. 2020;4:e138-e144.

40. Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus Disease-2019 Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. J Am Heart Assoc. 2021;10:e019650.

41. Hafra A, Mathai SV, Ball S, Bandyopadhyay D, Veyseh M, Chakraborty S, et al. Management of Thrombotic Complications in COVID-19: An Update. Drugs. 2020;80:1553–1562.

42. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-Related Severe Hypercoagulability and hypercoagulability in the outpatient setting. Thromb Res. 2020;192:122-123.

43. Emert R, Shah P, Zampella JG. COVID-19 and hypercoagulability in the outpatient setting. Thromb Res. 2020;192:122-123.

44. Wessels P. Hypercoagulability in COVID-19. SA Heart Journal. 2020;17 (3) Doi: 10.24170/17-3-4372

45. Nasir U, Ahmad S. Management and Perspective of Coronavirus Disease 2019 (COVID-19), Pregnancy, and Hypercoagulability. SN Compr Clin Med. 2021;3:1081-1084.

46. Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R. Hypercoagulability. SN Compr Clin Med. 2021;3:1081-1084.

47. Chandrakanth BS, Chandra J, Bhardwaj V, et al. Management of acute pulmonary embolism during COVID-19. JAMA Netw Open. 2021;4(6):e211381.

48. Patil S, Aggarwal R, Aggarwal R. COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2. Anesth Prog. 2021;68:132-136.

49. Siddiqi HK, Libby P. COVID-19 – A vascular disease. Trends Cardiovasc Med. 2021;21:1-5.

50. Hafra A, Mathai SV, Ball S, Bandyopadhyay D, Veyseh M, Chakraborty S, et al. Management of Thrombotic Complications in COVID-19: An Update. Drugs. 2020;80:1553–1562.

51. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-Related Severe Hypercoagulability and hypercoagulability in the outpatient setting. Thromb Res. 2020;192:122-123.

52. Wessels P. Hypercoagulability in COVID-19. SA Heart Journal. 2020;17 (3) Doi: 10.24170/17-3-4372

53. Nasir U, Ahmad S. Management and Perspective of Coronavirus Disease 2019 (COVID-19), Pregnancy, and Hypercoagulability. SN Compr Clin Med. 2021;3:1081-1084.

54. Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R. COVID-19 and Hypercoagulability. SN Compr Clin Med. 2021;3:1081-1084.

55. Chandrakanth BS, Chandra J, Bhardwaj V, et al. Management of acute pulmonary embolism during COVID-19. JAMA Netw Open. 2021;4(6):e211381.

56. Patil S, Aggarwal R, Aggarwal R. COVID-19: A prothrombotic and inflammatory disease caused by SARS coronavirus-2. Anesth Prog. 2021;68:132-136.